Clinical Trial Update: Complement Inhibition With Eculizumab for the Treatment of Non-Exudative Macular Degeneration (AMD) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating complement inhibition with eculizumab for non-exudative age-related macular degeneration has completed, with results posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• SOLIRIS (eculizumab)

Snippet

Sponsor: Philip J. Rosenfeld, MD, PhD | Conditions: Age-Related Macular Degeneration | Phase 2 | Status: COMPLETED | Results posted: 2015-01-26